The board of directors of Dingdang Health Technology Group Ltd. informed the shareholders of the Company and potential investors that, based on the preliminary assessment of management accounts of the Group for the six months ended June 30, 2023, the Group expects that as the fair value losses on the Company's shares with preferred rights (which were preference shares issued to pre-IPO investors) as financial liabilities at fair value through profit or loss and listing expenses did not recur for the Period after the completion of the Company's listing of its shares on The Stock Exchange of Hong Kong Limited in September 2022 and the decrease in share- based payments during the Period, the net loss for the Period may be narrowed by more than 70% as compared to the net loss of RMB 586 million for the corresponding period in 2022.